E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
|
E.1.1.1 | Medical condition in easily understood language |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Digestive System Diseases [C06] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.0 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10011401 |
E.1.2 | Term | Crohn's disease |
E.1.2 | System Organ Class | 10017947 - Gastrointestinal disorders |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
The primary objective of this study is to evaluate the efficacy of 2 different dose regimens of vedolizumab IV in pediatric subjects with moderately to severely active CD during maintenance therapy, based on clinical and endoscopic assessments at Week 54. |
|
E.2.2 | Secondary objectives of the trial |
- Efficacy of vedolizumab measured by clinical and endoscopic remission at Week 14 - Efficacy of vedolizumab measured by clinical and endoscopic remission at Week 54 - Efficacy of vedolizumab measured by sustained clinical and endoscopic remission at Week 54 - Effect of vedolizumab on clinical response over time up to Week 54 - Effect of vedolizumab on achieving corticosteroid-free remission at Week 54 - Effect of vedolizumab on clinical remission over time up to Week 54 - Efficacy of vedolizumab as measured by sustained clinical response at Week 54 - Efficacy of vedolizumab as measured by sustained endoscopic remission at Week 54 - Efficacy of vedolizumab as measured by sustained clinical remission at Week 54 - Vedolizumab PK in pediatric participants with active CD after IV administration - Safety in participants on maintenance therapy up to Week 54 - Immunogenicity of vedolizumab in participants - Effect of vedolizumab on patterns of growth and pubertal development |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
- The participants has moderately to severely active CD, unresponsive or intolerant to their current standard of care (SOC). - The participants weigh ≥10 kg at the time of screening and enrollment into the study. - Participants with Crohn's disease (CD) diagnosed at least 1 month before screening. Participants with moderately to severely active CD defined by a Pediatric Crohn’s Disease Activity Index (PCDAI) >30 and an simple endoscopic score for Crohn’s Disease (SES-CD) >6 (or an SES-CD ≥4 if disease is confined to terminal ileum) at screening endoscopy. - Participants who have failed, lost response to, or been intolerant to treatment with at least 1 of the following agents: corticosteroids, immunomodulators (eg, azathioprine (AZA), 6-mercaptopurine (6-MP), methotrexate [MTX]), and/or tumor necrosis factor (TNF)-α antagonist therapy (eg, infliximab, adalimumab). This includes participants who are dependent on corticosteroids or exclusive or partial enteral nutrition to control symptoms and who are experiencing worsening of disease in the moderate-to-severe range when attempting to wean off corticosteroids or discontinue exclusive enteral nutrition. - Participants with extensive colitis or pancolitis of >8 years' duration or left-sided colitis of >12 years' duration must have documented evidence of a negative surveillance colonoscopy within 12 months before screening. - Participants with vaccinations that are up-to-date based on the countrywide accepted schedule of childhood vaccines. |
|
E.4 | Principal exclusion criteria |
- Participants who have received either (1) an investigational biologic (other than those listed in Exclusion Criterion #1) within 60 days or 5 half-lives before screening (whichever is longer); or (2) an approved biologic or biosimilar agent within 2 weeks before the first dose of study drug or at any time during the screening period. - Participants with active cerebral/meningeal disease, signs/symptoms or history of progressive multifocal leukoencephalopathy (PML) or any other major neurological disorders including stroke, multiple sclerosis, brain tumor or neurodegenerative disease. - The participants had a clinically significant infection (eg, pneumonia, pyelonephritis, coronavirus disease 2019 [COVID-19]) within 30 days prior to first dose of study drug. - The participants has received any live vaccinations within 30 days prior to first dose. - Participants who currently require surgical intervention or are anticipated to require surgical intervention for CD during this study. - Participants who have had subtotal or total colectomy or have a jejunostomy, ileostomy, colostomy, ileo-anal pouch, known fixed stenosis of the intestine, short bowel syndrome, or >3 small intestine resections. - Participants with a current diagnosis of indeterminate colitis. - Participants with clinical features suggesting monogenic very early-onset inflammatory bowel disease. - Active or latent tuberculosis (TB), as evidenced by a diagnostic TB test performed within 30 days of screening or during the screening Period that is positive, defined as: -- Positive QuantiFERON test or 2 successive indeterminate QuantiFERON tests, OR -- A TB skin test reaction ≥5 mm. - Participants with evidence of positive hepatitis B surface antigen (HBsAg) or hepatitis B core antibody (HBcAb). Hepatitis B virus (HBV) immune subjects (ie, hepatitis B surface antigen [HBsAg]-negative and hepatitis B antibody–positive) may, however, be included. Note: If a participant tests negative for HBsAg, but positive for HBcAb, the participant would be considered eligible if the absence of HBV DNA is confirmed by HBV DNA polymerase chain reaction reflex testing performed in the central laboratory. - Participants with chronic hepatitis C virus (HCV) (ie, positive HCV antibody [HCVAb] and HCV RNA). Note: Participants who are HCVAb–positive without evidence of HCV RNA may be considered eligible (spontaneous viral clearance or previously treated and cured [defined as no evidence of HCV RNA at least 12 weeks before baseline]). - The participants has any identified congenital or acquired immunodeficiency (eg, common variable immunodeficiency, human immunodeficiency virus [HIV] infection, organ transplantation). - The participant has evidence of dysplasia or history of malignancy other than a successfully treated non-metastatic cutaneous squamous cell or basal cell carcinoma or localized carcinoma in situ of the cervix. - Participants with positive stool studies for ova and/or parasites or stool culture at screening visit. - Participants with positive Clostridioides difficile (C difficile) stool test at screening visit. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
1- Percentage of Participants With Clinical Remission at Week 54 Based on Pediatric Crohn's Disease Activity Index (PCDAI) Score ≤10 2- Percentage of Participants With Endoscopic Response at Week 54 Based on Simple Endoscopic Score for Crohn's Disease [SES-CD] Score Defined as at Least a 50% Reduction in SES-CD Score From Baseline |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
|
E.5.2 | Secondary end point(s) |
3- Percentage of Participants with Clinical and Endoscopic Remission at Week 14 Based on Both PCDAI Score ≤10 and SES-CD Score ≤4 with at Least a 2-point Reduction From Baseline and no Subscore >1 4- Percentage of Participants with Clinical and Endoscopic Remission at Week 54 Based on Both PCDAI ≤10 Score and SES-CD Score ≤4 With at Least a 2-point Reduction From Baseline and no Subscore >1 5- Percentage of Participants with Sustained Clinical and Endoscopic Remission at Week 54 6- Percentage of Participants with Corticosteroid-free Remission at Week 54 Based on PCDAI Score 7- Percentage of Participants with Sustained Endoscopic Remission Based on SES-CD Score at Week 14 8- Percentage of Participants with Sustained Endoscopic Remission Based on SES-CD Score at Week 54 9- Percentage of Participants with Sustained Clinical Remission at Week 14 Based on PCDAI Score 10- Percentage of Participants with Sustained Clinical Remission at Week 54 Based on PCDAI Score 11- Serum Trough Concentrations of Vedolizumab Over Time 12- Percentage of Participants With Positive Antivedolizumab Antibodies 13- Percentage of Participants With Positive Neutralizing Antivedolizumab Antibody Titers 14- Sustained Clinical Response at Week 14 Based on PCDAI Score 15- Sustained Clinical Response at Week 54 Based on PCDAI Score 16- Percentage of Participants with Clinical Remission at Weeks 2, 6, 10, 14, 22, 30, 38, 46, and 54 Based on a PCDAI <10 17- Percentage of Participants with Change in Baseline in Clinical Response at Weeks 2, 6, 10, 14, 22, 30, 38, 46, and 54 18- Percentage of Participants with at Least One Adverse Event (AE), Serious Adverse Event (SAE), and AE of special interest (AESI) 19- Change from Baseline in Weight 20- Change from Baseline in Linear Growth Z-score 21- Percentage of Participants with Tanner Stage V at Week 54 |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
3- Week 14 4- Week 54 5- Week 54 6- Week 54 7- Week 14 8- Week 54 9- Week 14 10- Week 54 11- Pre-dose and post-dose at multiple time points (up to 54 weeks) 12- Pre-dose (up to 54 weeks) 13- Pre-dose (up to 54 weeks) 14- Week 14 15- Week 54 16- Weeks 2, 6, 10, 14, 22, 30, 38, 46, and 54 17- Weeks 2, 6, 10, 14, 22, 30, 38, 46, and 54 18- From first dose of study drug before each dose on dosing days through the Week 72 19- Baseline up to Week 54 20- Baseline up to Week 54 21- Week 54 |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Information not present in EudraCT |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | Yes |
E.8.1.7.1 | Other trial design description |
open label induction with double blind maintenance |
|
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 9 |
E.8.3 |
Will this trial be conducted at a single site globally?
| No |
E.8.4 | Will this trial be conducted at multiple sites globally? | Yes |
E.8.6 Trial involving sites outside the EEA |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.6.3 | Specify the countries outside of the EEA in which trial sites are planned |
Ukraine |
Australia |
Canada |
China |
Israel |
Japan |
Korea, Republic of |
Russian Federation |
United Kingdom |
United States |
Belgium |
Croatia |
Czechia |
Greece |
Hungary |
Italy |
Lithuania |
Poland |
Slovakia |
Spain |
|
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
It has been defined as the last subject last visit |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.2 | In all countries concerned by the trial years | 2 |
E.8.9.2 | In all countries concerned by the trial months | 8 |